Immunoproteasome subunits as emerging contributors to neurodegeneration in Parkinson’s Disease
Objective: To gain comprehensive contribution of immunoproteasome in central nervous system of Parkinson's Disease Background: Recent investigations have elucidated that, in addition to the classical…Miniscope-based neural circuit profiling in freely behaving animals for preclinical therapeutic assessment
Objective: To advance translational research by revealing detailed relationships between neural circuit activity and behavioural symptoms in preclinical models Background: Conventional preclinical tests for CNS…Catalan MSA Registry (CMSAR): Applying new Clinical Criteria and Biomarkers for Increasing Diagnostic Accuracy, is New Better?
Objective: To reassess the CMSAR and determine if new criteria and new biomarkers can enhance diagnostic accuracy. Background: The CMSAR, conducted between 2015 and 2019,…α-Synuclein Pathology Across Movement Disorders and Neurodegenerative Diseases by Seed Amplification Assay
Objective: To assess the frequency of pathological α-synuclein (αSyn) in various movement disorders and neurodegenerative diseases from a specialized movement disorder clinic by αSyn seed…Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies
Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…Simulated Space Gravity Recapitulates Parkinson’s Disease Pathology in Neural Cell Model
Objective: This investigation centers on the potential influence of microgravity on α-synuclein aggregation, a hallmark feature of Parkinson's disease (PD) characterized by the formation of…Phenotypic characterization of an ATP13A2 knockout rat model of Parkinson’s disease
Objective: This project aimed to characterize the first-ever transgenic ATP13A2 knockout rat model to elucidate the underlying mechanisms of ATP13A2-associated pathology. Background: Most Parkinson’s disease…TOPAS-MSA: Targeting Oligomer Pathology of Alpha-Synuclein – A Study Evaluating the Safety and Efficacy of Emrusolmin in Patients with Multiple System Atrophy
Objective: The objective of the TOPAS-MSA study is to assess the safety and efficacy of emrusolmin (anle138b/TEV-56286), an orally bioavailable small molecule targeting aggregated α-synuclein,…Baseline and Longitudinal NSD-ISS Staging of the PPMI Cohort
Objective: To apply biological definition and Neuronal α-Synuclein Disease Integrated Staging System (NSD-ISS) to the PPMI baseline and longitudinal dataset. Background: The NSD-ISS Working Group…Motor Impact of Fasting in Parkinson’s Disease Patients: An overview
Objective: To provide a literature overview of fasting impact on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 51
- Next Page »